 WES MOORE, Governor  Ch. 323  
 
– 1 – Chapter 323  
(House Bill 1217 ) 
 
AN ACT concerning  
 
Maryland Medical Assistance Program and Health Insurance – Required 
Coverage for Biomarker Testing  
 
FOR the purpose of requiring the Maryland Medical Assistance Program and certain 
insurers, nonprofit health service plans, health maintenance organizations, and 
managed care organizations to provide coverage for biomarker testing that is 
supported by medic al and scientific evidence; establishing requirements for 
deductibles, copayments, coinsurance, and utilization review for biomarker testing; 
and generally relating to the coverage of biomarker testing by the Maryland Medical 
Assistance Program and health insurance carriers.  
 
BY adding to  
 Article – Health – General  
Section 15 –102.3(k) and 15 –103(a)(2)(xxii)  
 Annotated Code of Maryland  
 (2019 Replacement Volume and 2022 Supplement)  
 
BY repealing and reenacting, without amendments,  
 Article – Health – General  
Section 15 –103(a)(1)  
 Annotated Code of Maryland  
 (2019 Replacement Volume and 2022 Supplement)  
 
BY repealing and reenacting, with amendments,  
 Article – Health – General  
Section 15 –103(a)(2)(xx) and (xxi)  
 Annotated Code of Maryland  
 (2019 Replace ment Volume and 2022 Supplement)  
 
BY adding to  
 Article – Insurance  
Section 15 –859 
 Annotated Code of Maryland  
 (2017 Replacement Volume and 2022 Supplement)  
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 
That the Laws of Maryland read as follows:  
 
Article – Health – General  
 
15–102.3.  
Ch. 323  2023 LAWS OF MARYLAND   
 
– 2 –  
 (K) THE BEGINNING JULY 1, 2025,  THE PROVISIONS OF § 15–859 OF THE 
INSURANCE ARTICLE APPLY TO MANA GED CARE ORGANIZATIO NS IN THE SAME 
MANNER THEY APPLY TO  CARRIERS . 
 
15–103. 
 
 (a) (1) The Secretary shall administer the Maryland Medical Assistance 
Program.  
 
  (2) The Program:  
 
   (xx) Beginning on July 1, 2023, shall provide, subject to federal 
approval and limitations of the State budget, community violence prevention services in 
accordance with § 15 –141.3  of this subtitle; [and] 
 
   (xxi) Beginning on January 1, 2023, shall provide, subject to the 
limitations of the State budget, and as permitted by federal law, coverage for self –measured 
blood pressure monitoring for all Program recipients diagnosed with uncontrolled high 
blood pressure, including:  
 
    1. The provision of validated home blood pressure monitors; 
and 
 
    2. Reimbursement of health care provider and other staff 
time used for patient training, transmission of blood pressure data, interpretat ion of blood 
pressure readings and reporting, and the delivery of co –interventions, including 
educational materials or classes, behavioral change management, and medication 
management ; AND  
 
   (XXII) BEGINNING ON JANUARY 1, 2024  JULY 1, 2025 , SHALL 
PROVIDE , SUBJECT TO THE LIMIT ATIONS OF THE STATE BUDGET , AND AS 
PERMITTED BY FEDERAL  LAW, COVERAGE FOR BIOMARK ER TESTING IN 
ACCORDANCE WITH § 15–859 OF THE INSURANCE ARTICLE . 
 
Article – Insurance  
 
15–859. 
 
 (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 
INDICATED . 
 
  (2) (I) “BIOMARKER ” MEANS A CHARACTERIST IC THAT IS 
OBJECTIVELY MEASURED  AND EVALUATED AS AN INDICATOR OF NORMAL 
BIOLOGICAL PROCESSES , PATHOGENIC PROCESSES , OR PHARMACOLOGIC 
 WES MOORE, Governor  Ch. 323  
 
– 3 – RESPONSES TO A SPECI FIC THERAPEUTIC INTE RVENTION , INCLUDING KNOWN 
GENE–DRUG INTERACTIONS FO R MEDICATIONS BEING CONSIDERED FOR USE O R 
ALREADY BEING ADMINI STERED .  
 
   (II) “BIOMARKER ” INCLUDES GENE MUTATI ONS, 
CHARACTERISTICS OF G ENES , OR PROTEIN EXPRESSIO N.  
 
  (3) (I) “BIOMARKER TESTING ” IS THE ANALYSIS OF A  PATIEN T’S 
TISSUE , BLOOD , OR OTHER BIOSPECIMEN  FOR THE PRESENCE OF A BIOMARKER , 
THE RESULTS OF WHICH : 
 
    1. PROVIDE INFORMATION THAT MAY BE USED IN THE 
FORMULATION OF A TRE ATMENT OR MONITORING  STRATEGY THAT INFORM S A 
PATIENT ’S OUTCOME AND IMPACT S THE CLINICAL D ECISION ; AND  
 
    2. INCLUDE BOTH INFORMA TION THAT IS ACTIONA BLE 
AND SOME INFORMATION  THAT CANNOT BE IMMED IATELY USED IN THE 
FORMULATION OF A CLI NICAL DECISION . 
 
   (II) “BIOMARKER TESTING ” INCLUDES SINGLE –ANALYTE 
TESTS , MULTI–PLEX PANEL TESTS , PROTEIN EXP RESSION , AND WHOLE EXOME , 
WHOLE GENOME , AND WHOLE TRANSCRIPT OME SEQUENCING .  
 
 (B) THIS SECTION APPLIES TO: 
 
  (1) INSURERS AND NONPROF IT HEALTH SERVICE PL ANS THAT 
PROVIDE HOSPITAL , MEDICAL , OR SURGICAL BENEFITS  TO INDIVIDUALS OR GR OUPS 
ON AN EXPENSE –INCUR RED BASIS UNDER HEAL TH INSURANCE POLICIE S OR 
CONTRACTS THAT ARE I SSUED OR DELIVERED I N THE STATE ; AND 
 
  (2) HEALTH MAINTENANCE O RGANIZATIONS THAT PR OVIDE 
HOSPITAL , MEDICAL , OR SURGICAL BENEFITS  TO INDIVIDUALS OR GR OUPS UNDER 
CONTRACTS THAT ARE I SSUED OR D ELIVERED IN THE STATE . 
 
 (C) AN ENTITY SUBJECT TO THIS SECTION SHALL P ROVIDE COVERAGE FOR 
BIOMARKER TESTING FO R THE PURPOSE OF DIA GNOSIS , TREATMENT , APPROPRIATE 
MANAGEMENT , OR ONGOING MONITORIN G OF A DISEASE OR CO NDITION THAT IS 
SUPPORTED BY MEDICAL  AND SC IENTIFIC EVIDENCE , INCLUDING TESTING : 
 
  (1) CLEARED OR APPROVED BY THE U.S.  FOOD AND DRUG 
ADMINISTRATION ; 
 
Ch. 323  2023 LAWS OF MARYLAND   
 
– 4 –   (2) REQUIRED OR RECOMMEN DED FOR A DRUG APPRO VED BY THE 
U.S.  FOOD AND DRUG ADMINISTRATION TO ENS URE AN INSURED OR EN ROLLEE IS 
A GOOD CANDIDATE FOR  THE DRUG TREATMENT ; 
 
  (3) REQUIRED OR RECOMMEN DED THROUGH A WARNIN G OR 
PRECAUTION FOR A DRU G APPROVED BY THE U.S.  FOOD AND DRUG 
ADMINISTRATION TO IDE NTIFY WHETHER AN INS URED OR ENROLLEE WIL L HAVE AN 
ADVERSE REACTION TO THE DRUG TREATMENT O R DOSAGE ; 
 
  (4) COVERED UNDER A CENTERS FOR MEDICARE AND MEDICAID 
SERVICES NATIONAL COVERAGE DETERMINATION OR MEDICARE 
ADMINISTRATIVE CONTRACTOR LOCAL COVERAGE DETERMINATION ; OR  
 
  (5) SUPPORTED BY NATIONA LLY RECOGNIZED CLINI CAL PRACTICE 
GUIDELINES THAT ARE : 
 
   (I) DEV ELOPED BY INDEPENDEN T ORGANIZATIONS OR 
MEDICAL PROFESSIONAL  SOCIETIES USING A TR ANSPARENT METHODOLOG Y AND 
REPORTING STRUCTURE AND THAT HAVE A CONF LICT OF INTEREST POL ICY; AND 
 
   (II) ESTABLISHED STANDARD S OF CARE INFORMED B Y A 
SYSTEMATIC REVIEW OF  EVIDENC E AND AN ASSESSMENT OF THE BENEFITS AND 
RISKS OF ALTERNATIVE  CARE OPTIONS AND INC LUDE RECOMMENDATIONS  
INTENDED TO OPTIMIZE  PATIENT CARE ; OR 
 
  (6) SUPPORTED BY CONSENS US STATEMENTS THAT A RE: 
 
   (I) DEVELOPED BY AN INDE PENDENT , MULTIDISCIPLINARY  
PANEL OF E XPERTS USING A TRANS PARENT METHODOLOGY A ND REPORTING  
STRUCTURE AND THAT H AVE A CONFLICT OF IN TEREST POLICY ; AND  
 
   (II) AIMED AT SPECIFIC CL INICAL CIRCUMSTANCES  AND BASE  
THE STATEMENTS ON TH E BEST AVAILABLE EVI DENCE FOR THE PURPOS E OF  
OPTIMIZING THE OUTCOMES OF CLINICAL  CARE . 
 
 (D) AN ENTITY SUBJECT TO THIS SECTION SHALL E NSURE THAT THE 
COVERAGE REQUIRED UN DER SUBSECTION (C) OF THIS SECTION IS P ROVIDED IN A 
MANNER THAT LIMITS D ISRUPTIONS IN CARE I NCLUDING THE NEED FO R MULTIPLE 
BIOPSIES OR BIOSPECI MEN SAMPLES .  
 
 (E) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , THE 
COVERAGE REQUIRED UN DER THIS SECTION MAY  BE SUBJECT TO THE AN NUAL 
DEDUCTIBLES , COPAYMENTS , OR COINSURANCE REQUI REMENTS IMPOSED BY A N 
 WES MOORE, Governor  Ch. 323  
 
– 5 – ENTITY SUBJECT TO TH IS SECTION FOR SIMIL AR COVERAGES U NDER THE SAME 
HEALTH INSURANCE POL ICY OR CONTRACT . 
 
  (2) THE ANNUAL DEDUCTIBLE S, COPAYMENTS , OR COINSURANCE 
REQUIREMENTS IMPOSED  UNDER PARAGRAPH (1) OF THIS SUBSECTION F OR THE 
COVERAGE REQUIRED UN DER THIS SECTION MAY  NOT BE GREATER THAN THE 
ANNUAL DEDUCTI BLES , COPAYMENTS , OR COINSURANCE REQUI REMENTS IMPOSED 
BY THE ENTITY FOR SI MILAR COVERAGES . 
 
 (F) (1) AN ENTITY SUBJECT TO THIS SECTION THAT RE QUIRES PRIOR  
AUTHORIZATION OR A S IMILAR UTILIZATION R EVIEW PROCEDURE FOR THE 
COVERAGE REQUIRED UN DER SUBSECTION (C) OF THIS SECTION SHAL L MAKE A  
DETERMINATION REGARD ING A REQUEST FOR AP PROVAL WHEN SUBMITTE D 
ELECTRONICALLY : 
 
   (I) IN REAL TIME IF THE B IOMARKER TESTING IS TO GUIDE THE  
PROVISION OF PHARMAC EUTICAL SERVICES THA T ARE URGENT AND NO  
ADDITIONAL INFORMATI ON IS  NEEDED TO PROCESS TH E REQUEST ; AND  
 
   (II) FOR OTHER REQUESTS , IN ACCORDANCE WITH §  
19–108.2  OF THE HEALTH – GENERAL ARTICLE . 
 
  (2) IF A RESPONSE TO A PR IOR AUTHORIZATION OR  SIMILAR  
UTILIZATION REVIEW R EQUEST FOR APPROVAL IS NOT RECEIVED IN T HE TIME  
FRAMES REQUIRED UNDE R THIS SUBSECTION , THE REQUEST SHALL BE  
CONSIDERED APPROVED . 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That on or before December 1, 
2024, the Maryland Department of Health shall report to the Governor and, in accordance 
with § 2 –1257 of the State Government Article, the General Assembly on the following:  
 
  (1) the fiscal impact of the biomarkers  biomarker  testing coverage required 
under Section 1 of this Act on the Maryland Medical Assistance Program’s policy on 
biomarkers  biomarker  testing coverage for specific cancers during fiscal year 2024;  
 
  (2) any available data on use of biomarkers  biomarker  testing by race and 
ethnicity in the Program;  
 
  (3) the anticipated fiscal and access impacts of expanding the coverage 
required under Section 1 of this Act to the Maryland Medical Assistance Program in fiscal 
year 2026; and  
 
  (4) whether to establish a cap on the amount of reimbursement for 
biomarker testing coverage and, if recommended:  
 
Ch. 323  2023 LAWS OF MARYLAND   
 
– 6 –    (i) the recommended cap amount; and  
 
   (ii) the anticipated fiscal and access impacts of establishing the cap; 
and 
 
  (4) (5) recommendations on any legislative changes to the requirements 
established under Section 1 of this Act relating to the Maryland Medical Assistance 
Program, including managed  care organizations.  
 
 SECTION 3. AND BE IT FURTHER ENACTED, That on or before December 1, 
2025, the Maryland Health Care Commission shall report to the Senate Finance Committee 
and the House Health and Government Operations Committee, in accordance with §  
2–1257 of the State Government Article, on the impact of providing biomarker testing 
coverage required under Section 1 of this Act, including an analysis of the impact of 
providing access to biomarker testing to individuals based on race, gender, age, a nd public 
or private insurance.  
 
 SECTION 2. 4. AND BE IT FURTHER ENACTED, That Section 1 of  this Act shall 
apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the 
State on or after January 1, 2024.  
 
 SECTION 3. 5. AND BE IT FURTHER ENACTED, That this Act shall take effect 
January 1, 2024.  
 
Approved by the Governor, May 3, 2023.  